G
Gradient Denervation Technologies
Developing a novel endovascular, catheter-based technology to treat pulmonary hypertension
About Gradient Denervation Technologies
Gradient Denervation Technologies is a Paris-based medical device startup that focuses on the development of a unique, minimally invasive ultrasound-based catheter. This device is designed to treat heart failure patients who also suffer from pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. The company's innovative therapeutic approach aims to improve cardiovascular health.
The company's target market includes patients suffering from Group 2 pulmonary hypertension, which is heart failure accompanied by high pulmonary vascular resistance. The company's business model revolves around the development, clinical testing, and eventual commercialization of its novel catheter-based system.
Gradient Denervation Technologies recently closed a €14m Series A funding round led by Sabadell Asabys, with participation from Thuja Capital and founding investor Sofinnova Partners. These funds will be used to advance the clinical development of the company's device.
The company has already enrolled its first patient in a first-in-human clinical study, marking a significant milestone in its journey. The company is led by CEO Martin Grasse, a veteran with over 15 years in the medical device industry.
In summary, Gradient Denervation Technologies is a promising startup in the medical device sector, with a focus on improving the lives of heart failure patients with associated pulmonary hypertension. Its innovative, minimally invasive device has the potential to revolutionize treatment in this area.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Paris, France
- Employees
- 18
- Open positions
- 1
- Dealroom signal
- 78.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Catheters, Pulmonary, European Health Catapult (EIT Health), European Health Catapult 2020 (EIT Health), EIT Health
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2023 | $15M | $62M | Sofinnova Partners · Thuja Capital · Asabys Partners | ↗ |
| SUPPORT PROGRAM✓Other financing | Jun 2022 | $0 | — | MedTech Innovator | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Gradient Denervation Technologies is 540 monthly website visits, down 25% over the last three months. Gradient Denervation Technologies's team grew 20% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
MD Start Accelerator
Sofinnova Partners
Series A2 investors entered at this stage
Asabys Partners
Thuja Capital
Other known investors2 additional known investors
EIT Health
MedTech Innovator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gradient Denervation Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gradient Denervation Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.